## SAFETY DATA SHEET



UVILUX 1745-02 - RILLETOP TS 21150 STØVET GRØN

# SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product name : UVILUX 1745-02 - RILLETOP TS 21150 STØVET GRØN

1.2 Relevant identified uses of the substance or mixture and uses advised against

Product use : Paint.

1.3 Details of the supplier of the safety data sheet

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

e-mail address of person : Prod-safe@teknos.com

responsible for this SDS

**National contact** 

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

1.4 Emergency telephone number

**National advisory body/Poison Centre** 

Telephone number : National Poisons Information Centre: 01 809 2566

#### **SECTION 2: Hazards identification**

#### 2.1 Classification of the substance or mixture

**Product definition**: Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Skin Irrit. 2, H315 Eye Dam. 1, H318 Skin Sens. 1, H317 Aquatic Chronic 3, H412

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

#### 2.2 Label elements

Hazard pictograms





Signal word : Danger

**Hazard statements** : H315 - Causes skin irritation.

H317 - May cause an allergic skin reaction. H318 - Causes serious eye damage.

H412 - Harmful to aquatic life with long lasting effects.

**Precautionary statements** 

**Prevention**: P280 - Wear protective gloves. Wear eye or face protection.

P273 - Avoid release to the environment.

P261 - Avoid breathing vapour.

Response : P305 + P351 + P338 + P310 - IF IN EYES: Rinse cautiously with water for several

minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

**Label No** : 74697

Immediately call a POISON CENTER or doctor.

Date of issue/Date of revision : 30/11/2023 Date of previous issue : 13/07/2022 Version : 1.03 1/18

#### SECTION 2: Hazards identification

**Storage** 

: Not applicable.

**Disposal** 

: P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.

**Hazardous ingredients** 

: Contains: Dipropylenglycol diacrylate; 4,4'-Isopropylidenediphenol, oligomeric reaction products with 1-chloro-2,3-epoxypropane, esters with acrylic acid; Hexanedioic acid, polymer with (chloromethyl)oxirane, 2-ethyl-2-(hydroxymethyl) -1,3-propanediol, 4,4'-(1-methylethylidene)bis[phenol] and oxirane, 2-propenoate and Methylbenzoylformiat

Supplemental label elements

: Warning! Hazardous respirable droplets may be formed when sprayed. Do not breathe spray or mist.

**Annex XVII - Restrictions** on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

#### 2.3 Other hazards

Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII

: This mixture does not contain any substances that are assessed to be a PBT or a

Other hazards which do not result in classification : None known.

## SECTION 3: Composition/information on ingredients

3.2 Mixtures : Mixture

| Product/ingredient name   | Identifiers  | %         | Classification  | Specific Conc.<br>Limits, M-factors<br>and ATEs | Туре    |
|---|--|-----------|---|---|---------|
| <b>D</b> ípropylenglycol diacrylate   | REACH #:<br>01-2119484629-21<br>EC: 260-754-3<br>CAS: 57472-68-1 | ≥25 - ≤50 | Skin Irrit. 2, H315<br>Eye Dam. 1, H318<br>Skin Sens. 1, H317 | -   | [1]     |
| titanium dioxide  | REACH #:<br>01-2119489379-17<br>EC: 236-675-5<br>CAS: 13463-67-7 | ≥10 - ≤25 | Carc. 2, H351<br>(inhalation)                                 | -   | [1] [*] |
| 4,4'-Isopropylidenediphenol, oligomeric reaction products with 1-chloro-2,3-epoxypropane, esters with acrylic acid  | REACH #:<br>01-2119490020-53<br>EC: 500-130-2<br>CAS: 55818-57-0 | ≥10 - <25 | Skin Sens. 1, H317<br>Aquatic Chronic 2,<br>H411              | -   | [1]     |
| Hexanedioic acid, polymer with (chloromethyl)oxirane, 2-ethyl-2-(hydroxymethyl) -1,3-propanediol, 4,4'-(1-methylethylidene)bis [phenol] and oxirane, 2-propenoate | CAS: 184181-05-3   | ≤10       | Skin Sens. 1, H317  | -   | [1]     |
| Methylbenzoylformiat  | REACH #:<br>01-2120101338-67<br>EC: 239-263-3<br>CAS: 15206-55-0 | ≤3        | Skin Sens. 1, H317  | -   | [1]     |
| Benzene, (1-methylethenyl)-, homopolymer, ar-   | CAS: 163702-01-0   | <3        | Repr. 2, H361f  | -   | [1]     |

Date of issue/Date of revision : 30/11/2023 Date of previous issue : 13/07/2022 Version : 1.03 2/18 Label No : 74697

## **SECTION 3: Composition/information on ingredients**

| SECTION 3: Compo   | Sition/illioilliati  |      | greulents   |  |         |
|--|--|------|---|--|---------|
| (2-hydroxy-2-methyl-<br>1-oxopropyl) derivs.                               |  |      |   |  |         |
| Propylidynetrimethanol, ethoxylated, esters with acrylic acid              | REACH #:<br>01-2119489900-30<br>EC: 500-066-5<br>CAS: 28961-43-5                         | ≤3   | Eye Irrit. 2, H319<br>Skin Sens. 1, H317<br>Aquatic Chronic 3,<br>H412  | -  | [1]     |
| Phosphine oxide, phenylbis (2,4,6-trimethylbenzoyl)-                       | REACH #:<br>01-2119489401-38<br>EC: 423-340-5<br>CAS: 162881-26-7<br>Index: 015-189-00-5 | ≤3   | Skin Sens. 1A, H317<br>Aquatic Chronic 4,<br>H413   | -  | [1]     |
| 2-Methoxy-1-methylethyl acetate  | REACH #:<br>01-2119475791-29<br>EC: 203-603-9<br>CAS: 108-65-6<br>Index: 607-195-00-7    | ≤3   | Flam. Liq. 3, H226<br>STOT SE 3, H336   | -  | [1] [2] |
| pentaerythritol tetraacrylate  | CAS: 917379-62-5   | <1   | Acute Tox. 4, H302<br>Skin Irrit. 2, H315<br>Eye Dam. 1, H318<br>Skin Sens. 1, H317<br>Aquatic Chronic 2,<br>H411                   | ATE [Oral] = 500<br>mg/kg  | [1]     |
| (1-methyl-1,2-ethanediyl)bis<br>[oxy(methyl-2,1-ethanediyl)]<br>diacrylate | REACH #:<br>01-2119484613-34<br>EC: 256-032-2<br>CAS: 42978-66-5<br>Index: 607-249-00-X  | <1   | Skin Irrit. 2, H315<br>Eye Irrit. 2, H319<br>Skin Sens. 1, H317<br>STOT SE 3, H335<br>Aquatic Chronic 2,<br>H411                    | STOT SE 3, H335:<br>C ≥ 10%  | [1]     |
| 2-Butoxyethanol  | REACH #:<br>01-2119475108-36<br>EC: 203-905-0<br>CAS: 111-76-2<br>Index: 603-014-00-0    | <1   | Acute Tox. 4, H302<br>Acute Tox. 3, H331<br>Skin Irrit. 2, H315<br>Eye Irrit. 2, H319   | ATE [Oral] = 1200<br>mg/kg<br>ATE [Inhalation<br>(vapours)] = 3 mg/l | [1] [2] |
| Propylidynetrimethanol, ethoxylated, esters with acrylic acid              | REACH #:<br>01-2119489900-30<br>EC: 500-066-5<br>CAS: 28961-43-5                         | ≤0.3 | Eye Irrit. 2, H319 Skin Sens. 1B, H317 Aquatic Chronic 3, H412 See Section 16 for the full text of the H statements declared above. | -  | [1]     |

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

- [1] Substance classified with a health or environmental hazard
- [2] Substance with a workplace exposure limit
- [\*] The classification as a carcinogen by inhalation applies only to mixtures placed on the market in powder form containing 1% or more of titanium dioxide particles with aerodynamic diameter ≤ 10 µm not bound within a matrix.

Occupational exposure limits, if available, are listed in Section 8.

Date of issue/Date of revision : 30/11/2023 Date of previous issue : 13/07/2022 Version : 1.03 3/18 **Label No** : **7**4697

### **SECTION 4: First aid measures**

#### 4.1 Description of first aid measures

**Eye contact** 

: Get medical attention immediately. Call a poison center or physician. Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Chemical burns must be treated promptly by a physician.

Inhalation

: Get medical attention immediately. Call a poison center or physician. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

**Skin contact** 

: Get medical attention immediately. Call a poison center or physician. Wash with plenty of soap and water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Chemical burns must be treated promptly by a physician. In the event of any complaints or symptoms, avoid further exposure. Wash clothing before reuse. Clean shoes thoroughly before reuse.

Ingestion

: Get medical attention immediately. Call a poison center or physician. Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Chemical burns must be treated promptly by a physician. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

#### **Protection of first-aiders**

: No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

#### 4.2 Most important symptoms and effects, both acute and delayed

#### Over-exposure signs/symptoms

**Eye contact**: Adverse symptoms may include the following:

pain watering redness

Inhalation : No specific data.

**Skin contact**: Adverse symptoms may include the following:

pain or irritation

redness

blistering may occur

**Ingestion**: Adverse symptoms may include the following:

stomach pains

#### 4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician : Treat symptomatically. Contact poison treatment specialist immediately if large

quantities have been ingested or inhaled.

**Specific treatments** : No specific treatment.

Date of issue/Date of revision : 30/11/2023 Date of previous issue : 13/07/2022 Version : 1.03 4/18

**Label No** : 74697

### SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

Suitable extinguishing media

: Use an extinguishing agent suitable for the surrounding fire.

**Unsuitable extinguishing** media

: None known.

#### 5.2 Special hazards arising from the substance or mixture

Hazards from the substance or mixture : In a fire or if heated, a pressure increase will occur and the container may burst. This material is harmful to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain.

**Hazardous combustion** products

: Decomposition products may include the following materials: carbon dioxide carbon monoxide

phosphorus oxides halogenated compounds metal oxide/oxides

#### 5.3 Advice for firefighters

**Special protective actions** for fire-fighters

: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

**Special protective** equipment for fire-fighters Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

#### SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Do not breathe vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.

For emergency responders: If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

#### 6.2 Environmental precautions

: Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful to the environment if released in large quantities.

#### 6.3 Methods and material for containment and cleaning up

**Small spill** 

Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

#### Large spill

: Stop leak if without risk. Move containers from spill area. Approach the release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilt product.

**Label No** : 74697

Date of issue/Date of revision : 30/11/2023 · 13/07/2022 Version : 1.03 5/18 Date of previous issue

#### **SECTION 6: Accidental release measures**

## 6.4 Reference to other sections

: See Section 1 for emergency contact information.

See Section 8 for information on appropriate personal protective equipment.

See Section 13 for additional waste treatment information.

### SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

#### 7.1 Precautions for safe handling

#### **Protective measures**

Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems should not be employed in any process in which this product is used. Do not get in eyes or on skin or clothing. Do not breathe vapour or mist. Do not ingest. Avoid release to the environment. If during normal use the material presents a respiratory hazard, use only with adequate ventilation or wear appropriate respirator. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.

## Advice on general occupational hygiene

Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

#### 7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.

#### 7.3 Specific end use(s)

Recommendations : Not available.
Industrial sector specific : Not available.
solutions

### **SECTION 8: Exposure controls/personal protection**

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

#### 8.1 Control parameters

#### **Occupational exposure limits**

| Product/ingredient name                          | Exposure limit values  |  |  |  |  |
|--|--|--|--|--|--|
| 2-Methoxy-1-methylethyl acetate  2-Butoxyethanol | NAOSH (Ireland, 5/2021). Absorbed through skin. Notes: EU derived Occupational Exposure Limit Values  OELV-8hr: 50 ppm 8 hours.  OELV-8hr: 275 mg/m³ 8 hours.  OELV-15min: 100 ppm 15 minutes.  OELV-15min: 550 mg/m³ 15 minutes.  NAOSH (Ireland, 5/2021). Absorbed through skin. Notes: EU derived Occupational Exposure Limit Values  OELV-8hr: 20 ppm 8 hours.  OELV-8hr: 98 mg/m³ 8 hours.  OELV-15min: 50 ppm 15 minutes.  OELV-15min: 246 mg/m³ 15 minutes. |  |  |  |  |

**Biological exposure indices** 

 Date of issue/Date of revision
 : 30/11/2023
 Date of previous issue
 : 13/07/2022
 Version
 : 1.03
 6/18

 UVILUX 1745-02 - RILLETOP TS 21150 STØVET GRØN
 Label No : 7/4697

## **SECTION 8: Exposure controls/personal protection**

| Product/ingredient name | Exposure indices   |
|-------------------------|--|
|                         | NAOSH (Ireland, 1/2011)  BMGV: 200 mg/g creatinine, BAA [in urine]. Sampling time: end of shift - As soon as possible after exposure ceases. |

## Recommended monitoring procedures

European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

#### **DNELs/DMELs**

| Product/ingredient name  | Туре                 | Exposure   | Value   | Population   | Effects                          |
|--|----------------------|--|---|--|----------------------------------|
| Dipropylenglycol diacrylate  | DNEL                 | Long term Dermal   | 1.66 mg/<br>kg bw/day                           | General population   | Systemic                         |
|  | DNEL                 | Long term Oral   | 2.08 mg/<br>kg bw/day                           | General population   | Systemic                         |
|  | DNEL                 | Long term Dermal   | 2.77 mg/<br>kg bw/day                           | Workers  | Systemic                         |
|  | DNEL                 | Long term<br>Inhalation  | 7.24 mg/m <sup>3</sup>                          | General<br>population                                      | Systemic                         |
|  | DNEL                 | Long term<br>Inhalation  | 24.48 mg/<br>m³                                 | Workers  | Systemic                         |
| 4,4'-Isopropylidenediphenol, oligomeric reaction products with 1-chloro-2,3-epoxypropane, esters | DNEL                 | Long term<br>Inhalation  | 1.17 mg/m³                                      | Workers  | Systemic                         |
| with acrylic acid  | DNEL                 | Long term Dermal   | 33 mg/kg  | Workers  | Systemic                         |
| Methylbenzoylformiat   | DNEL                 | Long term Oral   | bw/day<br>1.67 mg/<br>kg bw/day                 | General<br>population                                      | Systemic                         |
|  | DNEL                 | Long term Dermal   | 1.67 mg/<br>kg bw/day                           | General<br>population                                      | Systemic                         |
|  | DNEL                 | Long term Dermal   | 3.33 mg/<br>kg bw/day                           | Workers  | Systemic                         |
| Benzene, (1-methylethenyl)-,<br>homopolymer, ar-(2-hydroxy-<br>2-methyl-1-oxopropyl) derivs.     | DNEL                 | Long term Oral   | 5.28 µg/kg<br>bw/day                            | General<br>population                                      | Systemic                         |
|  | DNEL                 | Long term Dermal   | 5.28 µg/kg<br>bw/day                            | General population   | Systemic                         |
|  | DNEL                 | Long term<br>Inhalation  | 9.18 μg/m³                                      | General<br>population                                      | Systemic                         |
|  | DNEL                 | Long term Dermal   | 14.8 µg/kg<br>bw/day                            | Workers  | Systemic                         |
|  | DNEL                 | Long term<br>Inhalation  | 52.1 μg/m³                                      | Workers  | Systemic                         |
| Propylidynetrimethanol, ethoxylated, esters with acrylic acid                                    | DNEL                 | Long term Dermal   | 10.5 mg/<br>kg bw/day                           | Workers  | Systemic                         |
| ,  | DNEL                 | Long term<br>Inhalation  | 37 mg/m <sup>3</sup>                            | Workers  | Systemic                         |
| Phosphine oxide, phenylbis (2,4,6-trimethylbenzoyl)-   | DNEL                 | Long term<br>Inhalation  | 21 mg/m <sup>3</sup>                            | Workers  | Systemic                         |
|  | DNEL                 | Short term<br>Inhalation   | 21 mg/m³  | Workers  | Systemic                         |
|  | DNEL<br>DNEL<br>DNEL | Long term Dermal<br>Short term Dermal<br>Long term<br>Inhalation | 3.3 mg/kg<br>3.3 mg/kg<br>5.2 mg/m <sup>3</sup> | Workers<br>Workers<br>General<br>population<br>[Consumers] | Systemic<br>Systemic<br>Systemic |
|  | DNEL                 | Long term Dermal   | 1.5 mg/kg                                       | General  | Systemic                         |

Date of issue/Date of revision

: 30/11/2023 Date of previous issue

: 13/07/2022

Version : 1.03 7/18

UVILUX 1745-02 - RILLETOP TS 21150 STØVET GRØN

**Label No** : **7**4697

## SECTION 8: Exposure controls/personal protection

| DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL  | <u> </u>                            |       |                    |                       |            |            |
|--|-------------------------------------|-------|--------------------|-----------------------|------------|------------|
| DNEL   DNEL   Short term Oral   1.5 mg/kg   General   Systemic     |                                     |       |                    |                       | population |            |
| DNEL DNEL Long term Dratal bw/day DNEL Long term Dermal DNEL Short term Dratal DNEL Dong term Dermal DNEL Dong term Dnem Dnem Dnem Dnem Dnem Dnem Dnem Dne   |                                     |       |                    |                       |            |            |
| DNEL   DNEL   DNEL   Long term Dermal   1.67 ng/kg   General   Dnet      |                                     | DNEL  | Long term Oral     | 1.5 mg/kg             |            | Systemic   |
| DNEL   |                                     |       |                    |                       |            |            |
| DNEL DNEL Long term Oral DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL   |                                     |       |                    |                       |            |            |
| DNEL Dong term Dermal Inhalation DNEL Dong term Dermal DNEL Dong term Dnemator Dne |                                     | DNEL  | Short term Oral    | 1.67 ng/kg            | General    | Systemic   |
| DNEL DNEL Long term Dermal DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL   |                                     |       |                    | bw/day                | population |            |
| DNEL DNEL Long term Dermal DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL   |                                     | DNEL  | Long term Oral     | 1.5 mg/kg             | General    | Systemic   |
| DNEL Dong term Dermal DNEL DNEL DNEL DNEL DNEL DNEL Dong term Dermal DNED DONG DEPONDENT DONG DEPONDENT DEPO |                                     |       |                    |                       | population | •          |
| DNEL   Short term Dermal   DNEL   Short term Dermal   DNEL   Short term   Inhalation   DNEL   |                                     | DNEL  | Long term Dermal   | 1.5 mg/kg             |            | Systemic   |
| DNEL   Short term Dermal   1,67 mg/s   General population   Systemic   Systemic population   Systemic popula   |                                     |       |                    |                       | population |            |
| DNEL Ong term Inhalation DNEL Cong term Dermal DNEL Cong term DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL   |                                     | DNEL  | Short term Dermal  |                       |            | Systemic   |
| DNEL      |                                     |       |                    |                       |            |            |
| DNEL Long term Inhalation DNEL Short term Dermal DNEL Long term Inhalation DNEL Long term Dermal DNEL Dong term Inhalation DNEL Dong term Dermal DNEL Dong term Dong term Inhalation DNEL Dong term Dong term Inhalation DNEL Long term ONEL Long term Inhalation DNEL Long term ONEL Short term ONE  |                                     | DNEL  | Short term         |                       |            | Systemic   |
| DNEL   Long term   1.93 mg/m²   General population   Systemic   Systemic   DNEL   Short term Dermal   Systemic   Systemic   Workers   Systemic   Systemi   |                                     |       |                    | J. J.                 |            |            |
| Inhalation   DNEL   Long term Dermal   Systemic   DNEL   Long term Dermal   Systemic   DNEL   Long term   Systemic   DNEL   Short term     |                                     | DNFI  |                    | 1 93 mg/m³            |            | Systemic   |
| DNEL Dong term Dermal Dwilday 3.33 mg/kg bw/day 3.33 mg/mg/mg/day 3.33 mg/mg/mg/mg/mg/mg/mg/mg/mg/mg/mg/mg/mg/m  |                                     | DIVLE |                    | 1.00 mg/m             |            | Cyclonic   |
| DNEL   Short term Dermal   Systemic   Syst   |                                     | DNEI  |                    | 3 ma/ka               |            | Systemic   |
| DNEL   Short term Dermal   3.3 mg/k kg bw/day   Workers   Systemic   Workers   Systemic   Systemic   Net   N |                                     | DIVLE | Long term Bernar   |                       | WOIKCIO    | Cyclenno   |
| DNEL Inhalation DNEL Long term (Inhalation DNEL Long term (Inhalation DNEL Long term (Inhalation DNEL Long term (Inhalation DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL  |                                     | DNEI  | Short term Dermal  |                       | Workers    | Systemic   |
| DNEL Long term Inhalation DNEL DNEL Long term Inhalation DNEL DNEL Long term Inhalation DNEL DNEL Long term Dermal DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL   |                                     | DIVLE | Chort tolli Dellia |                       | TTOINGIG   | Systemio   |
| 2-Methoxy-1-methylethyl acetate  DNEL linhalation Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Oral Long term Oral Inhalation DNEL Long term Dermal Inhalation DNEL Short term Oral DNEL Long term Dermal Inhalation DNEL Short term Oral DNEL Short term Inhalation DNEL Short term Inhalat |                                     | DNE   | Short term         |                       | Workers    | Systemic   |
| 2-Methoxy-1-methylethyl acetate  DNEL   Long term   Inhalation   DNEL   Long term   DNEL   DNEL   Long term   DNEL   DNEL   DNEL   Short term   Short term   DNEL   Short term   DNEL   Short term   DNEL   Short |                                     | DINCL |                    | 7.04 mg/m             | WOIKEIS    | Systernic  |
| 2-Methoxy-1-methylethyl acetate  DNEL   DNEL   Long term   lnhalation   |                                     | DNEI  |                    | 7 01 ma/m3            | Markoro    | Systemia   |
| 2-Methoxy-1-methylethyl acetate    DNEL   Long term   Inhalation   DNEL   Long term   DNEL   DNEL   Long term   DNEL   DNEL   Long term   DNEL   DNEL   Long term   DNEL   DNEL   Long term   DNEL   Long term   DNEL   Long term   DNEL   DNEL   Long term   DNEL   DNEL   DNEL   DNEL   Long term   DNEL   DNEL  |                                     | DINEL |                    | 7.04 Hig/III          | Workers    | Systemic   |
| Inhalation   DNEL   Long term   Oral   DNEL   Long term   DNEL   Long term   DNEL   DNEL   Long term   DNEL   DNEL   Long term   DNEL   | 2 Mathavy 1 mathylathyl agatata     | DNE   |                    | 22 ma/m3              | Conoral    | Local      |
| DNEL Long term Inhalation DNEL Long term Oral S6 mg/kg bw/day 275 mg/m³ Workers Systemic DNEL Long term Dermal DNEL Dermal DNEL Long term Dermal DNEL Dermal DNEL Dong term Dermal DNEL Dong term Dermal DNEL Dong term Dermal DNEL Dong term DNEL Dermal DNEL Dermal DNEL Dong term DNEL DNE DNED DNED DNED DNED DNED DNED  | 2-Methoxy-1-methylethyl acetate     | DINEL |                    | 33 mg/m <sup>3</sup>  |            | Local      |
| Inhalation   Long term Oral   Systemic   S   |                                     | DAIEI |                    | 00/3                  |            | 0          |
| DNEL   Long term Oral   275 mg/m3   Workers   Systemic   Systemic  |                                     | DNEL  |                    | 33 mg/m <sup>3</sup>  |            | Systemic   |
| DNEL   Long term   |                                     | DATE  |                    | 00 //                 |            |            |
| DNEL   Long term   |                                     | DNEL  | Long term Oral     |                       |            | Systemic   |
| Inhalation   DNEL   Long term Dermal   Systemic   DNEL   Long term Dermal   DNEL   DNEL   Long term Dermal   DNEL    |                                     | 51151 |                    |                       |            |            |
| DNEL   Long term Dermal   Systemic   DNEL   DNEL   Short term   Inhalation   DNEL   Long term Dermal   Systemic   DNEL   DNEL   Long term Dermal   Systemic   DNEL   D   |                                     | DNEL  |                    | 275 mg/m <sup>3</sup> | Workers    | Systemic   |
| DNEL Short term Inhalation DNEL Long term Dermal Inhalation DNEL Cong term Dormal Inhalation DNEL Cong term Oral Inhalation DNEL Cong term Inhalation DNEL Cong term Oral Inhalation DNEL Cong term Dormal Inhalation DNEL DNET DORMAL TOTAL DORMAL TOTAL DORMAL T |                                     |       |                    |                       |            |            |
| DNEL   Short term   Inhalation   DNEL   Long term Dermal   Morkers   Local   |                                     | DNEL  | Long term Dermal   |                       |            | Systemic   |
| Inhalation   Cong term Dermal    |                                     |       |                    |                       |            |            |
| DNEL   Long term Dermal   T96 mg/kg bw/day   1.7    |                                     | DNEL  |                    | 550 mg/m <sup>3</sup> | Workers    | Local      |
| (1-methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)] diacrylate  DNEL Long term Dermal  DNEL Long term Oral  DNEL Cong term Oral  DNEL Cong term Oral  DNEL Cong term Oral  DNEL Orang term Oral  DNEL O |                                     |       | Inhalation         |                       |            |            |
| (1-methyl-1,2-ethanediyl)bis[oxy (methyl-2,1-ethanediyl)] diacrylate     DNEL Dong term Dermal Inhalation     1.7 mg/kg bw/day 2.35 mg/m³ Workers     Workers     Systemic       2-Butoxyethanol     DNEL Dong term Oral Inhalation     6.3 mg/kg bw/day 26.7 mg/kg bw/day     General population General population General population Workers     Systemic Dong term Population General population Morkers     Systemic Population General population Morkers       DNEL Dong term Inhalation DNEL Short term Inha   |                                     | DNEL  | Long term Dermal   | 796 mg/kg             | Workers    | Systemic   |
| (methyl-2,1-ethanediyl)] diacrylate     DNEL DNEL Long term Inhalation     bw/day 2.35 mg/m³ Workers     Systemic       2-Butoxyethanol     DNEL DNEL Long term Oral DNEL Short term Oral Inhalation     6.3 mg/kg bw/day bw/day bw/day population General population General population Systemic population General population DNEL Short term Inhalation DNEL Short term Inhala   |                                     |       |                    | bw/day                |            |            |
| DNEL Long term Inhalation DNEL Short term Oral DNEL Long term Sp mg/m³ Inhalation DNEL Long term Inhalation DNEL Short term Oral DNEL Oral Drawlation DNEL Oral D | (1-methyl-1,2-ethanediyl)bis[oxy    | DNEL  | Long term Dermal   | 1.7 mg/kg             | Workers    | Systemic   |
| DNEL Long term Inhalation DNEL Short term Oral DNEL Long term Sp mg/m³ Inhalation DNEL Long term Inhalation DNEL Short term Oral DNEL Oral Drawlation DNEL Oral D | (methyl-2,1-ethanediyl)] diacrylate |       |                    | bw/day                |            |            |
| 2-Butoxyethanol  DNEL   Cong term Oral   Cong term    |                                     | DNEL  | Long term          |                       | Workers    | Systemic   |
| 2-Butoxyethanol  DNEL   Long term Oral   Systemic   DNEL   Long term Oral   Systemic   DNEL   Long term Oral   Systemic   |                                     |       | •                  |                       |            | _          |
| DNEL Short term Oral Systemic population General population Workers Systemic population Workers Systemic Inhalation DNEL Short term 147 mg/m³ General population DNEL Short term 147 mg/m³ General population Workers Local Inhalation DNEL Short term 246 mg/m³ Workers Local Inhalation DNEL Short term 1091 mg/ population Workers Systemic Propylidynetrimethanol, ethoxylated, esters with acrylic acid DNEL Long term Dermal Systemic Systemic Workers Systemic Systemic Systemic Norters Systemic Sy | 2-Butoxyethanol                     | DNEL  |                    | 6.3 mg/kg             | General    | Systemic   |
| DNEL Short term Oral 26.7 mg/ kg bw/day 59 mg/m³ General population General population Workers Systemic population DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Dermal Systemic Sy |                                     |       |                    |                       |            |            |
| DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Dermal DNEL Long term Dermal Systemic System |                                     | DNEL  | Short term Oral    |                       |            | Systemic   |
| DNEL Long term Inhalation DNEL Short term Inhala |                                     |       |                    |                       |            |            |
| Inhalation DNEL Short term Inhalation DNEL Short |                                     | DNEL  | Long term          |                       |            | Systemic   |
| DNEL Long term Inhalation DNEL Short term Inhala |                                     |       |                    | 22                    |            | ,          |
| Inhalation DNEL Short term Inhalation DNEL Short |                                     | DNFI  |                    | 98 ma/m³              |            | Systemic   |
| DNEL Short term Inhalation DNEL Short term 246 mg/m³ Workers  DNEL Short term 426 mg/m³ General population DNEL Short term Inhalation DNEL Short term 426 mg/m³ General population UNEL Short term 1091 mg/ population DNEL Short term 1091 mg/ Workers  Propylidynetrimethanol, ethoxylated, esters with acrylic acid  DNEL Long term Dermal 10.5 mg/ kg bw/day DNEL Long term 37 mg/m³ Workers  Systemic  Systemic  Systemic  Systemic   |                                     |       |                    | 30g/!!!               |            | 2,000.1110 |
| Inhalation DNEL Short term Inhalation DNEL Short |                                     | DNFI  |                    | 147 ma/m³             | General    | Local      |
| DNEL Short term Inhalation DNEL Short term 426 mg/m³ General population DNEL Short term 1091 mg/ m³ Workers  Propylidynetrimethanol, ethoxylated, esters with acrylic acid  DNEL Long term 246 mg/m³ General population Workers Systemic  1091 mg/ m³ Workers  Systemic  Norkers Systemic  Norkers Systemic  Norkers Systemic  Norkers Systemic  Systemic  Norkers Systemic  |                                     |       |                    |                       |            |            |
| DNEL Short term 1091 mg/ population Norkers Systemic 1091 mg/ m³  Propylidynetrimethanol, ethoxylated, esters with acrylic acid DNEL Long term 1091 mg/ kg bw/day 37 mg/m³  Workers Systemic Systemic Norkers Norkers Systemic Norkers Norkers Norkers Systemic Norkers Nor |                                     | DNE   |                    | 246 mg/m <sup>3</sup> |            | Local      |
| DNEL Short term Inhalation DNEL Long term Dermal Systemic Systemic DNEL Long term Dermal Systemic Systemic Systemic Systemic Systemic Systemic Systemic Systemic Systemic DNEL Long term Systemic Systemi |                                     | DIVLE |                    | 270 mg/m              | AAOIKEIS   | Local      |
| Propylidynetrimethanol, ethoxylated, esters with acrylic acid    Inhalation   Short term   1091 mg/   m³   Workers   Systemic   Syst |                                     | DNE   |                    | 126 ma/m <sup>3</sup> | General    | Systemic   |
| Propylidynetrimethanol, ethoxylated, esters with acrylic acid  DNEL Short term Inhalation DNEL Long term Dermal DNEL Long term Dermal Systemic Syst |                                     | DIVEL |                    | 720 mg/m              |            | Cysternic  |
| Propylidynetrimethanol, ethoxylated, esters with acrylic acid    DNEL   Long term Dermal   10.5 mg/ kg bw/day   37 mg/m³   Workers   Systemic   |                                     | חאבי  |                    | 1001 ==/              |            | Systemia   |
| Propylidynetrimethanol, ethoxylated, esters with acrylic acid  DNEL Long term Dermal kg bw/day 37 mg/m³ Workers  Systemic Systemic   |                                     | DINEL |                    | m <sup>3</sup>        | WUIKEIS    | Systemic   |
| esters with acrylic acid   | Dranylidynatrimathanal athawilata   | ראבי  |                    |                       | Morkora    | Cyatamia   |
| DNEL Long term 37 mg/m³ Workers Systemic   |                                     | DINEL | Long term Dermal   | •                     | vvoikeis   | Systemic   |
|  | esters with acrylic acid            | ראבי  | l ong to           |                       | \\/orkers  | Cyatara:a  |
| Innaiation   |                                     | DNEL  |                    | 3/ mg/m <sup>3</sup>  | vvorkers   | Systemic   |
|  |                                     |       | irinaiation        |                       |            |            |

## **PNECs**

No PNECs available

 Date of issue/Date of revision
 : 30/11/2023
 Date of previous issue
 : 13/07/2022
 Version
 : 1.03
 8/18

 UVILUX 1745-02 - RILLETOP TS 21150 STØVET GRØN
 Label No : 7/4697

## **SECTION 8: Exposure controls/personal protection**

#### 8.2 Exposure controls

Appropriate engineering controls

: If user operations generate dust, fumes, gas, vapour or mist, use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits.

#### Individual protection measures

**Hygiene measures** 

: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

#### **Eye/face protection**

: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles and/or face shield. If inhalation hazards exist, a full-face respirator may be required instead.

#### **Skin protection**

**Hand protection** 

: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.

Recommendations: Wear suitable gloves tested to EN374.

< 1 hour (breakthrough time): Nitrile gloves. thickness > 0.3 mm

1 - 4 hours (breakthrough time): 4H / Silver Shield® gloves.

**Body protection** 

: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection

: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

**Respiratory protection** 

: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Filter type: A

Filter type (spray application): A P

**Environmental exposure** controls

: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

**Label No** : **7**4697

## SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

#### 9.1 Information on basic physical and chemical properties

**Appearance** 

Physical state: Liquid.Colour: Green.Odour: Slight

Odour threshold : Not available.

Melting point/freezing point : Not available.

Date of issue/Date of revision : 30/11/2023 Date of previous issue : 13/07/2022 Version : 1.03 9/18

## **SECTION 9: Physical and chemical properties**

Initial boiling point and boiling range

| Ingredient name   | °C    | °F     | Method   |
|---|-------|--------|----------|
| Methoxy-1-methylethyl acetate                                 | 145.8 | 294.4  | OECD 103 |
| Propylidynetrimethanol, ethoxylated, esters with acrylic acid | >391  | >735.8 | OECD 103 |

**Flammability** : Not available.

Lower and upper explosion

limit

Lower: Not applicable. Upper: Not applicable.

: Closed cup: >100°C (>212°F) Flash point

**Auto-ignition temperature** 

| Ingredient name                 | °C  | °F    | Method    |
|---------------------------------|-----|-------|-----------|
| přpropylenglycol diacrylate     | 240 | 464   | DIN 51794 |
| 2-Methoxy-1-methylethyl acetate | 333 | 631.4 | DIN 51794 |

**Decomposition temperature** : Not available.

Not applicable. pН **Viscosity** Not available.

Solubility(ies)

Not available.

: Not available. Solubility in water Partition coefficient: n-octanol/ : Not applicable.

Vapour pressure

|                               | Vapour Pressure at 20°C |          |          | Va    | oour pressu | re at 50°C |
|-------------------------------|-------------------------|----------|----------|-------|-------------|------------|
| Ingredient name               | mm Hg                   | kPa      | Method   | mm Hg | kPa         | Method     |
| Methoxy-1-methylethyl acetate | 2.7                     | 0.36     | OECD 104 |       |             |            |
| Dipropylenglycol diacrylate   | 0.00064                 | 0.000085 | OECD 104 |       |             |            |

: Not available. **Relative density** : 1.4 g/cm<sup>3</sup> **Density** Vapour density : Not available. : Not available. **Explosive properties** : Not available. **Oxidising properties** 

**Particle characteristics** 

Median particle size : Not applicable.

### SECTION 10: Stability and reactivity

10.1 Reactivity : No specific test data related to reactivity available for this product or its ingredients.

10.2 Chemical stability : The product is stable.

10.3 Possibility of hazardous reactions : Under normal conditions of storage and use, hazardous reactions will not occur.

10.4 Conditions to avoid : No specific data.

10.5 Incompatible materials : No specific data.

Date of issue/Date of revision : 30/11/2023 Date of previous issue : 13/07/2022 Version : 1.03 10/18 Label No : 74697

## **SECTION 10: Stability and reactivity**

10.6 Hazardous decomposition products : Under normal conditions of storage and use, hazardous decomposition products should not be produced.

## **SECTION 11: Toxicological information**

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

#### **Acute toxicity**

| Product/ingredient name  | Result      | Species | Dose        | Exposure |
|--|-------------|---------|-------------|----------|
| pipropylenglycol diacrylate  | LD50 Oral   | Rat     | 4600 mg/kg  | -        |
| Propylidynetrimethanol, ethoxylated, esters with acrylic acid              | LD50 Dermal | Rabbit  | >13 g/kg    | -        |
| Phosphine oxide, phenylbis (2,4,6-trimethylbenzoyl)-                       | LD50 Oral   | Rat     | >2000 mg/kg | -        |
| 2-Methoxy-1-methylethyl acetate  | LD50 Dermal | Rabbit  | >5 g/kg     | -        |
|  | LD50 Oral   | Rat     | 8532 mg/kg  | -        |
| (1-methyl-1,2-ethanediyl)bis<br>[oxy(methyl-2,1-ethanediyl)]<br>diacrylate | LD50 Oral   | Rat     | 6200 mg/kg  | -        |
| Propylidynetrimethanol, ethoxylated, esters with acrylic acid              | LD50 Dermal | Rabbit  | >13 g/kg    | -        |

### **Conclusion/Summary**

: Based on available data, the classification criteria are not met.

#### **Acute toxicity estimates**

| Route              | ATE value   |  |  |
|--------------------|-------------|--|--|
| halation (vapours) | 750.19 mg/l |  |  |

#### **Irritation/Corrosion**

| Product/ingredient name  | Result                   | Species | Score | Exposure             | Observation |
|--|--------------------------|---------|-------|----------------------|-------------|
| <b>万</b> ipropylenglycol diacrylate  | Eyes - Severe irritant   | Rabbit  | -     | 100 mg               | -           |
|  | Skin - Severe irritant   | Rabbit  | -     | 500 mg               | -           |
| titanium dioxide   | Skin - Mild irritant     | Human   | -     | 72 hours 300<br>ug l | -           |
| Propylidynetrimethanol, ethoxylated, esters with acrylic acid              | Eyes - Moderate irritant | Rabbit  | -     | 100 mg               | -           |
|  | Skin - Moderate irritant | Rabbit  | -     | 500 mg               | -           |
| (1-methyl-1,2-ethanediyl)bis<br>[oxy(methyl-2,1-ethanediyl)]<br>diacrylate | Eyes - Severe irritant   | Rabbit  | -     | 24 hours 100<br>uL   | -           |
|  | Skin - Moderate irritant | Rabbit  | -     | 500 mg               | -           |
| 2-Butoxyethanol  | Eyes - Moderate irritant | Rabbit  | -     | 24 hours 100<br>mg   | -           |
|  | Eyes - Severe irritant   | Rabbit  | -     | 100 mg               | -           |
|  | Skin - Mild irritant     | Rabbit  | -     | 500 mg               | -           |
| Propylidynetrimethanol, ethoxylated, esters with acrylic acid              | Eyes - Moderate irritant | Rabbit  | -     | 100 mg               | -           |
|  | Skin - Moderate irritant | Rabbit  | -     | 500 mg               | -           |

#### **Conclusion/Summary**

: Causes skin irritation.

#### **Sensitisation**

| Product/ingredient name                              | Route of exposure | Species    | Result      |
|--|-------------------|------------|-------------|
| Phosphine oxide, phenylbis (2,4,6-trimethylbenzoyl)- | skin              | Guinea pig | Sensitising |

## **Conclusion/Summary**

: May cause an allergic skin reaction.

**Mutagenicity** 

Date of issue/Date of revision : 30/11/2023 Date of previous issue : 13/07/2022 Version : 1.03 11/18 Label No : 74697

## SECTION 11: Toxicological information

| Product/ingredient name                              | Test | Experiment        | Result   |
|--|------|-------------------|----------|
| Phosphine oxide, phenylbis (2,4,6-trimethylbenzoyl)- | -    | Subject: Bacteria | Negative |

**Conclusion/Summary** : Based on available data, the classification criteria are not met.

Carcinogenicity

It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantities leading to significant impairment of particle clearance mechanisms in the lung.

**Conclusion/Summary** : Based on available data, the classification criteria are not met.

Reproductive toxicity

**Conclusion/Summary** : Based on available data, the classification criteria are not met.

**Teratogenicity** 

**Conclusion/Summary** : Based on available data, the classification criteria are not met.

Specific target organ toxicity (single exposure)

| Product/ingredient name   | Category                 | Route of exposure | Target organs                                       |
|---|--------------------------|-------------------|---|
| Methoxy-1-methylethyl acetate<br>(1-methyl-1,2-ethanediyl)bis[oxy(methyl-2,1-ethanediyl)]<br>diacrylate | Category 3<br>Category 3 | -                 | Narcotic effects<br>Respiratory tract<br>irritation |

### Specific target organ toxicity (repeated exposure)

Not available.

#### **Aspiration hazard**

Not available.

Information on likely routes : Not available.

of exposure

#### Potential acute health effects

**Eve contact** : Causes serious eye damage.

: No known significant effects or critical hazards. Inhalation

**Skin contact** : Causes skin irritation. May cause an allergic skin reaction.

Ingestion : No known significant effects or critical hazards.

#### Symptoms related to the physical, chemical and toxicological characteristics

**Eye contact** : Adverse symptoms may include the following:

> pain watering redness

Inhalation : No specific data.

Skin contact Adverse symptoms may include the following:

pain or irritation

redness

blistering may occur

Ingestion Adverse symptoms may include the following:

stomach pains

#### Delayed and immediate effects as well as chronic effects from short and long-term exposure

**Short term exposure** 

**Potential immediate** : Not available.

effects

Potential delayed effects : Not available.

**Long term exposure** 

**Potential immediate** : Not available.

effects

Version : 1.03 12/18 Date of issue/Date of revision : 30/11/2023 : 13/07/2022 Date of previous issue **Label No** : **7**4697

## **SECTION 11: Toxicological information**

Potential delayed effects : Not available.

Potential chronic health effects

Not available.

**Conclusion/Summary**: Not available.

General : Once sensitized, a severe allergic reaction may occur when subsequently exposed

to very low levels.

Carcinogenicity : No known significant effects or critical hazards.
 Mutagenicity : No known significant effects or critical hazards.
 Reproductive toxicity : No known significant effects or critical hazards.

#### 11.2 Information on other hazards

#### 11.2.1 Endocrine disrupting properties

Not available.

11.2.2 Other information

Not available.

## **SECTION 12: Ecological information**

#### 12.1 Toxicity

| Product/ingredient name                              | Result                                | Species                                       | Exposure |
|--|---------------------------------------|---|----------|
| titanium dioxide                                     | Acute LC50 3 mg/l Fresh water         | Crustaceans - Ceriodaphnia<br>dubia - Neonate | 48 hours |
|  | Acute LC50 6.5 mg/l Fresh water       | Daphnia - <i>Daphnia pulex</i> - Neonate      | 48 hours |
|  | Acute LC50 >1000000 μg/l Marine water | Fish - Fundulus heteroclitus                  | 96 hours |
| Phosphine oxide, phenylbis (2,4,6-trimethylbenzoyl)- | EC50 ≥0.26 mg/l                       | Aquatic plants - Desmodesmus subspicatus      | 72 hours |
|  | NOEC ≥0.008 mg/l Fresh water          | Daphnia - Daphnia magna                       | 21 days  |
|  | Acute EC50 >1.175 mg/l                | Daphnia - <i>Daphnia magna</i>                | 48 hours |
|  | Acute LC50 >0.09 mg/l                 | Fish - Brachydanio rerio                      | 96 hours |
| 2-Butoxyethanol                                      | Acute EC50 >1000 mg/l Fresh water     | Daphnia - Daphnia magna                       | 48 hours |
|  | Acute LC50 800000 µg/l Marine water   | Crustaceans - Crangon crangon                 | 48 hours |
|  | Acute LC50 1250000 µg/l Marine water  | Fish - Menidia beryllina                      | 96 hours |

**Conclusion/Summary** 

: Harmful to aquatic life with long lasting effects.

#### 12.2 Persistence and degradability

**Conclusion/Summary**: This product has not been tested for biodegradation.

| <b>Photolysis</b> | Biodegradability     |
|-------------------|----------------------|
| -                 | Readily  Not readily |
|                   | Photolysis<br>-<br>- |

#### 12.3 Bioaccumulative potential

| Product/ingredient name  | LogPow                   | BCF | Potential  |
|--|--------------------------|-----|------------|
| pipropylenglycol diacrylate 4,4'-lsopropylidenediphenol,           | 0.01 to 0.39<br>1.6 to 3 | -   | Low<br>Low |
| oligomeric reaction products with 1-chloro-                        | 1.0 to 3                 |     | Low        |
| 2,3-epoxypropane, esters with acrylic acid Propylidynetrimethanol, | 2.89                     | -   | Low        |
| ethoxylated, esters with acrylic acid                              |                          |     |            |

 Date of issue/Date of revision
 : 30/11/2023
 Date of previous issue
 : 13/07/2022
 Version
 : 1.03
 13/18

 UVILUX 1745-02 - RILLETOP TS 21150 STØVET GRØN
 Label No : ₹4697

#### **SECTION 12: Ecological information** Phosphine oxide, phenylbis 5.77 <5 Low (2,4,6-trimethylbenzoyl)-2-Methoxy-1-methylethyl 1.2 Low acetate (1-methyl-1,2-ethanediyl)bis 2 Low [oxy(methyl-2,1-ethanediyl)] diacrylate 2-Butoxyethanol 0.81 I ow Propylidynetrimethanol, 2.89 Low ethoxylated, esters with acrylic acid

#### 12.4 Mobility in soil

Soil/water partition coefficient (Koc)

: Not available.

: Not available. **Mobility** 

#### 12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

#### 12.6 Endocrine disrupting properties

Not available.

#### 12.7 Other adverse effects

No known significant effects or critical hazards.

## SECTION 13: Disposal considerations

#### 13.1 Waste treatment methods

#### **Product**

**Methods of disposal** 

: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

: The classification of the product may meet the criteria for a hazardous waste.

**Hazardous waste** 

: 080111\*

**European waste** catalogue (EWC)

**Packaging** 

**Methods of disposal** 

: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

**Special precautions** 

This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

## **SECTION 14: Transport information**

Date of issue/Date of revision : 30/11/2023 Date of previous issue · 13/07/2022 Version : 1.03 14/18 **Label No** : 74697

## **SECTION 14: Transport information**

|                                  | ADR/RID        | ADN            | IMDG           | IATA           |
|----------------------------------|----------------|----------------|----------------|----------------|
| 14.1 UN number or ID number      | Not regulated. | Not regulated. | Not regulated. | Not regulated. |
| 14.2 UN proper shipping name     | -              | -              | -              | -              |
| 14.3 Transport hazard class(es)  | -              | -              | -              | -              |
| 14.4 Packing group               | -              | -              | -              | -              |
| 14.5<br>Environmental<br>hazards | No.            | No.            | No.            | No.            |

14.6 Special precautions for

: Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

14.7 Maritime transport in bulk according to IMO instruments

: Not relevant/applicable due to nature of the product.

## SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

**Annex XIV** 

None of the components are listed.

Substances of very high concern

None of the components are listed.

#### Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

| Product/ingredient name | %   | Designation [Usage] |
|-------------------------|-----|---------------------|
| <b>☑</b> VILUX 1745-02  | ≥90 | 3                   |

Labelling

**Other EU regulations** 

**Industrial emissions** : Not listed (integrated pollution

prevention and control) -

**Air** 

**Industrial emissions** : Not listed

(integrated pollution prevention and control) -

Water

: Not applicable. **Explosive precursors** Ozone depleting substances (1005/2009/EU)

Not listed.

Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

Date of issue/Date of revision : 30/11/2023 Date of previous issue · 13/07/2022 Version : 1.03 15/18 Label No : 74697

## **SECTION 15: Regulatory information**

#### **Persistent Organic Pollutants**

Not listed.

### **Seveso Directive**

This product is not controlled under the Seveso Directive.

#### **International regulations**

#### Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

### **Montreal Protocol**

Not listed.

#### **Stockholm Convention on Persistent Organic Pollutants**

Not listed.

#### **Rotterdam Convention on Prior Informed Consent (PIC)**

Not listed.

#### **UNECE Aarhus Protocol on POPs and Heavy Metals**

Not listed.

## 15.2 Chemical safety assessment

 This product contains substances for which Chemical Safety Assessments are still required.

### **SECTION 16: Other information**

Indicates information that has changed from previously issued version.

## Abbreviations and acronyms

: ATE = Acute Toxicity Estimate

CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No.

1272/2008]

DMEL = Derived Minimal Effect Level DNEL = Derived No Effect Level

EUH statement = CLP-specific Hazard statement

N/A = Not available

PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RRN = REACH Registration Number

SGG = Segregation Group

vPvB = Very Persistent and Very Bioaccumulative

#### Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

| Classification          | Justification      |
|-------------------------|--------------------|
| Skin Irrit. 2, H315     | Calculation method |
| Eye Dam. 1, H318        | Calculation method |
| Skin Sens. 1, H317      | Calculation method |
| Aquatic Chronic 3, H412 | Calculation method |

#### Full text of abbreviated H statements

| <b>⊬</b> 226 | Flammable liquid and vapour.                            |
|--------------|---|
| H302         | Harmful if swallowed.                                   |
| H315         | Causes skin irritation.                                 |
| H317         | May cause an allergic skin reaction.                    |
| H318         | Causes serious eye damage.                              |
| H319         | Causes serious eye irritation.                          |
| H331         | Toxic if inhaled.                                       |
| H335         | May cause respiratory irritation.                       |
| H336         | May cause drowsiness or dizziness.                      |
| H351         | Suspected of causing cancer.                            |
| H361f        | Suspected of damaging fertility.                        |
| H411         | Toxic to aquatic life with long lasting effects.        |
| H412         | Harmful to aquatic life with long lasting effects.      |
| H413         | May cause long lasting harmful effects to aquatic life. |

 Date of issue/Date of revision
 : 30/11/2023
 Date of previous issue
 : 13/07/2022
 Version
 : 1.03
 16/18

 UVILUX 1745-02 - RILLETOP TS 21150 STØVET GRØN
 Label No : 74697

#### SECTION 16: Other information

#### Full text of classifications [CLP/GHS]

Acute Tox. 3 **ACUTE TOXICITY - Category 3** Acute Tox. 4 **ACUTE TOXICITY - Category 4** 

Aquatic Chronic 2 LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 2 LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3 Aquatic Chronic 3 Aquatic Chronic 4 LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 4

Carc. 2 CARCINOGENICITY - Category 2

SERIOUS EYE DAMAGE/EYE IRRITATION - Category 1 Eye Dam. 1 Eve Irrit. 2 SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2

Flam. Liq. 3 FLAMMABLE LIQUIDS - Category 3 Repr. 2 REPRODUCTIVE TOXICITY - Category 2 Skin Irrit. 2 SKIN CORROSION/IRRITATION - Category 2

Skin Sens. 1 SKIN SENSITISATION - Category 1 Skin Sens. 1A SKIN SENSITISATION - Category 1A Skin Sens. 1B SKIN SENSITISATION - Category 1B

SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE - Category 3 STOT SE 3

Date of issue/ Date of

revision

: 30/11/2023

Date of previous issue : 13/07/2022

Version : 1.03

#### **Notice to reader**

The information in this SDS is based on the present state of our knowledge and on current laws. The product is not to be used for purposes other than those specified under section 1 without first obtaining written handling instructions. It is always the responsibility of the user to take all necessary steps to fulfil the demands set out in the local rules and legislation. The information in this SDS is meant to be a description of the safety requirements for our product. It is not to be considered a guarantee of the product's properties.

Date of issue/Date of revision · 13/07/2022 Version : 1.03 17/18 : 30/11/2023 Date of previous issue Label No : 74697

Date of issue/Date of revision : 30/11/2023 Date of previous issue : 13/07/2022 **Version** : 1.03 18/18 **Label No** :**7**4697